Antiarrhythmic Sotalol, Occlusion/Occlusion-like Syndrome in Rats, and Stable Gastric Pentadecapeptide BPC 157 Therapy

We focused on the first demonstration that antiarrhythmics, particularly class II and III antiarrhythmic beta-blocker sotalol can induce severe occlusion/occlusion-like syndrome in rats. In this syndrome, as similar syndromes with permanent occlusion of major vessels, peripheral central, other noxious procedures severely disable endothelium function, stable gastric pentadecapeptide BPC 157-collateral pathways activation, was a resolving therapy. After high dose (80 mg/kg intragastrically) 180 min study, there were cause-consequence lesions brain (swelling, intracerebral hemorrhage), congestion heart, lung, liver, kidney, gastrointestinal tract, bradycardia, intracranial (superior sagittal sinus), portal caval hypertension, aortal hypotension, widespread thrombosis, peripherally centrally. Major vessels failed (congested inferior superior mesenteric vein, collapsed azygos vein). 157 therapy (10 µg, 10 ng/kg given intragastrically at 5 or 90 sotalol-time) effectively counteracted sotalol-occlusion/occlusion-like syndrome. particular, eliminated heart dilatation, myocardial affecting coronary veins arteries, well vessels; lung parenchyma congestion, venous arterial attenuated centrally, sinus) pronounced hemorrhage. Further, and/or markedly tract congestion. Therefore, vein activation direct blood delivery essential for particular effects. Thus, preventing such events, responding adequately when event is risk, strongly advocates further